Welcome to
FIT Objective
To collect data that will help identify unmet medical needs for feline patients while supporting your clients and your practice. Data collection will focus on clinical disease states in cats being treated with Mirataz® (mirtazapine transdermal ointment) for unintended weight loss.
Background and Significance
Mirataz® (mirtazapine transdermal ointment) is FDA approved for the management of weight loss in cats. Cats often stop eating and may experience nausea and vomiting, which can result in unintended weight loss. This can occur with a variety of underlying diseases but is commonly seen with chronic kidney disease, cancer, hyperthyroidism, pancreatitis, inflammatory bowel disease, neoplasia, and liver disease, to name a few. This can also occur with environmental factors such as a change in diet, a new family member or pet introduced to the household, or other environmental stressors.
FIT will be a national, prospective, multi-veterinary site collection of data in cats who are being treated with Mirataz® to manage unintended weight loss. FIT is focused on disease state factors that influence prescribing for Mirataz®.
Design and Methods
- Owners of cats for which Mirataz® is prescribed will be required to sign an owner consent prior to participation.
- Participating veterinary clinics will be asked to complete two online questionnaires: 1) at the time Mirataz® is prescribed (INITIAL), and 2) following a 14 day treatment period (14 DAY). This includes answers to questions that need to be collected from the owner.
- If Mirataz® is prescribed again after the initial 14 day treatment period, optional questionnaires at 1 month (1MONTH) and 3 months (3MONTH) may be completed.
- The online questionnaires are to be completed by a clinic staff member which may be the veterinarian, veterinary technician/nurse, or other veterinary staff member.
Cats are prescribed Mirataz® at the discretion of the attending veterinarian and according to labeled instructions. Please visit KindredBio.com/mirataz-pi for full prescribing information. Cats may be removed from participation at any time, either at the will of the owner or upon recommendation by the attending veterinarian.
Questionnaire
Compensation
Step 1 – Enroll Your Practice
After signing up, you will be provided a login and password to enroll cats to the program, and submit the questionnaires. Once signed up you will receive your account information within 2 business days. If you’d prefer, you can also call us at (888) 502-2307 to speak with a FIT adviser and enroll over the phone.
Step 2 – Log In and Enroll a Cat or Submit a Questionnaire
After enrolling your practice, you can log in and enroll a cat or submit a questionnaire. Please remember, for each cat enrolled, an owner consent form is required and available for download here. If you have any questions about how to navigate the system to enter data, click the instructions link for more information or call (888) 502-2307 and a FIT adviser will help.
Mirataz® (mirtazapine transdermal ointment) is indicated for the management of weight loss in cats
Important Safety Information
Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients. Do not use in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves when handling/applying, wash hands after and avoid contact between the treated cat and people or other animals for 2 hours following application. Use with caution in cats with hepatic and kidney disease. Cat’s food intake should be monitored upon discontinuation. Safety has not been evaluated in cats less than 2 kg, less than six months of age or in breeding, pregnant or lactating cats. The most common adverse reactions observed during clinical trials were application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting.
For product label, including complete safety information please visit KindredBio.com/mirataz-pi, or contact KindredBio Professional Services at 888-608-2542.
Technical Information for your Clinic
Learn more about Mirataz®(mirtazapine transdermal ointment)
Mirtazapine’s Mechanism of Action
Assessing Body and Muscle Composition in Cats
Recognition and Progression of Feline Disease
How to Apply Mirataz® (mirtazapine transdermal ointment)
KINsights: The Unique Feline 1.0 Fit or Frail
KINsights: The Unique Feline 2.0 Weight Loss Syndromes
KINsights: The Unique Feline 3.0 From Finicky to Famine
KINsights: The Unique Feline 4.0 Unintentional Weight Loss
Resources for Veterinarian to Provide to Pet Owners
Recognition and Progression of Feline Disease
How to Apply Mirataz® (mirtazapine transdermal ointment)
The Aging Feline – Chronic Kidney Disease
The Aging Feline – Is My Cat Fit or Frail?
As this is commercial product, which is purchased and prescribed at your discretion, to report a suspected adverse event or product quality complaint please call 1-888-608-2542 or email ProfessionalServices@KindredBio.com
Mirataz is a registered trademark of Kindred Biosciences, Inc. in the United States and/or other countries. ©2018 Kindred Biosciences, Inc., Burlingame, CA 94010. All rights reserved.